in the absence of a submission from the holder of the marketing authorisation:
midostaurin (Rydapt®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
To read more Press Release articles, click here.